Slides
Page 1
Financial Results and Business Update for the Quarter Ended December 31, 2025 February 6, 2026
Page 2
For investor audiences only Forward-Looking Statements This presentation includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, potential uses of cash and capital allocation, research and development plans, the anticipated timing, costs, design, conduct and results of our ongoing and planned preclinical studies and clinical trials for our product candidates, and any commercial potential of our product candidates following applicable regulatory approvals, are forward-looking statements. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this presentation and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward -looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements. These forward-looking statements may be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the sections captioned “Risk Factors” and “Forward-Looking Statements” of our filings with the U.S. Securities and Exchange Commission, available at www.sec.gov and investor.roivant.com. We operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this presentation, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward -looking statements, whether as a result of new information, future events or otherwise. Non-GAAP Financial Information The discussions during this conference call will include certain financial measures that were not prepared in accordance with U.S. generally accepted accounting principles (GAAP). Additional information regarding non-GAAP financial measures can be found on slide 29 and in our earnings release furnished with our Current Report on Form 8 -K dated February 6, 2026. Any non-GAAP financial measures presented are not, and should not be viewed as, substitutes for financial measures required by U.S. GAAP, have no standardized meaning prescribed by U.S. GAAP and may not be comparable to the calculation of similar measures of other companies. Disclaimer This presentation is intended for the investor community only; it is not intended to promote the product candidates referenced herein or otherwise influence healthcare prescribing decisions. 2
Page 3
For investor audiences only 3 Roivant in 2026 Brepocitinib: Positive Topline Results From BEACON Study in CS Additional Program Highlights Financial Update Q&A Agenda
Page 4
Roivant in 2026
Page 5
For investor audiences only 5 Continued Execution Following a Strong 2025 Note: All drugs are investigational and subject to regulatory approvals. All catalyst timings are approximate, based on current expectations and, where applicable, contingent on FDA feedback, and may be subject to change. CS: cutaneous sarcoidosis; D2T RA: difficult- to-treat rheumatoid arthritis; PH-ILD: pulmonary hypertension associated with interstitial lung disease; GD: Graves’ disease Fully enrolled Ph2b study for IMVT-1402 in D2T RA Fully enrolled Ph2 study for mosliciguat in PH-ILD Immunovant $550M common stock financing extends cash runway to GD commercial launch Positive Ph2 results for brepocitinib in CS
Page 6
For investor audiences only 2026: Another Catalyst-Rich Year for Roivant For investor audiences only LNP litigation jury trial in US Moderna case in March 2026 Mosliciguat PH-ILD Ph2b topline data expected in 2H 2026 Initiation of brepocitinib CS Ph3 trial expected in 2026 Brepocitinib NIU Ph3 topline data expected in 2H 2026 PoC topline data expected for IMVT-1402 in CLE in 2H 2026 IMVT-1402 D2T RA potentially registrational topline data expected in 2H 2026 Note: All drugs are investigational and subject to regulatory approvals. All catalyst timings are approximate, based on current expectations and, where applicable, contingent on FDA feedback, and may be subject to change. All references are to calendar years 6
Page 7
For investor audiences only 7 Phase 1 Phase 2 Registrational Approved Brepocitinib DM NIU CS FcRn Franchise TED D2T RA GD MG CIDP SjD CLE Mosliciguat PH-ILD High-Value Pipeline, Delivering Series of Near-Term Catalysts Note: All drugs are investigational and subject to regulatory approvals. All catalyst timings are approximate, based on current expectations and, where applicable, contingent on FDA feedback, and may be subject to change. All references are to calendar years NDA filed Topline data 2H 2026 Phase 3 program initiation 2026 Topline data 2H 2026 Topline data 2027 Topline data 2027 Topline data 2028 Topline data 2028 Topline data 1H 2026 Topline data 2H 2026 Topline data 2H 2026
Page 8
For investor audiences only BEACON Topline Results February 6, 2026
Page 9
For investor audiences only Highlights of Phase 2 BEACON Study in Cutaneous Sarcoidosis (CS) Brepocitinib demonstrated highly compelling evidence of deep clinical benefit for patients with cutaneous sarcoidosis • Brepocitinib 45 mg achieved a placebo-adjusted improvement on mean CSAMI-A of 21.6 points (p<0.0001) • 100% of brepocitinib 45 mg patients compared to 14% of placebo patients achieved a CSAMI improvement of at least 10 points • 62% of brepocitinib 45 mg patients compared to 0% of placebo patients achieved CSAMI-A < 5 (functional remission) • 69% of brepocitinib 45 mg patients compared to 0% of placebo patients achieved IGA gold standard Clear (0) / Almost Clear (1) with 2-point improvement Rapid onset of action with sustained benefit over time • Both brepocitinib doses achieved statistically significant separation from placebo on mean CSAMI-A at every study visit, starting with Week 4 (first visit) Both brepocitinib 45 mg and 15 mg substantially outperformed placebo across all endpoints measured • Dose dependent-response was seen on endpoints with highest clinical bar and patient reported outcomes Brepocitinib was well-tolerated throughout the 16-week treatment period, with No SAEs and all AEs graded mild or moderate in severity • Brepocitinib safety database includes over 1,500 patients and subjects, with a safety profile consistent with approved JAK1 and TYK2 inhibitors Cutaneous sarcoidosis represents a disease of high unmet need with no approved therapies • BEACON represents first ever positive placebo-controlled trial for any therapy, a breakthrough for the field 9CSAMI-A: Cutaneous Sarcoidosis Activity and Morphology Instrument – Activity Subscore; KSQ: King’s Sarcoidosis Questionnaire; IGA: Investigator’s Global Assessment
Page 10
For investor audiences only 10 Unlike many common inflammatory skin diseases, inadequately treated cutaneous sarcoidosis can rapidly cause permanent scarring and destruction of bone, cartilage, and hair follicles Plaque cutaneous sarcoidosis affecting significant body surface area Lupus pernio (papular and plaque cutaneous sarcoidosis) Plaque cutaneous sarcoidosis resulting in scarring alopecia CS: Urgency to Treat Due to Risk of Permanent Damage, Face and Scalp Involvement, and Psychosocial Impacts Images adapted from Fernandez-Faith and McDonnell, Clinics in Dermatol (2007 )
Page 11
For investor audiences only 11 ~40K CS patients in the US1,2 ~16K Minimal to no activity in other organs No approved therapies for cutaneous sarcoidosis ~24K Both skin and other organ involvement (principally lung and/or eye)3 No approved therapies for sarcoidosis Brepocitinib Has the Potential to Become the On-Label Therapy of Choice for All Sarcoidosis Patients With Any Cutaneous Disease Cutaneous Sarcoidosis Alone Includes Eligible Population of ~40,000 Patients 1. Foundation for Sarcoidosis Research 2. Haimovic, et al., J Am Acad Dermatol (2012) 3. Altmeyer et al., Altmeyers Encycl (2025)
Page 12
For investor audiences only JAK1/TYK2 Inhibition Distinctively Targets Key Pathogenic Process in Sarcoidosis: Polarization and Recruitment of Effector T Cells IL-6 JAK1/JAK1 Promotes Th17 Polarization IL-12 TYK2/JAK2 Promotes Th1 Polarization IFNγ JAK1/JAK2 Sustains and Recruits Th1 Effector T Cells 12Adapted from Grunewald et al, Nat Rev Dis Primers (2019 )
Page 13
For investor audiences only Eligible Patients Skin disease activity: CSAMI-A ≥ 10 Permitted Background Therapy Oral IST, antimalarial, tetracycline antibiotic, and/or OCS Primary Endpoint Safety & Tolerability Efficacy Endpoints CSAMI-A CSA-IGA Patient Reported Outcomes BREPOCITINIB 15 MG QD (N = 11) BREPOCITINIB 45 MG QD (N = 13) PLACEBO (N = 7) Primary Endpoint 16-WEEK TREATMENT PERIOD 13 BEACON: Phase 2 Placebo-Controlled Study Evaluating Brepocitinib in Cutaneous Sarcoidosis N=31 adults with active cutaneous sarcoidosis Randomized 3:2:2 Mandatory OCS taper to 0 mg / day from Week 2-8 Topical steroids withdrawn prior to Day 1 13 For investor audiences onlyAll analyses reported using a treatment policy estimand strategy. CSAMI-A: Cutaneous Sarcoidosis Activity and Morphology Instrument-Activity Score; CSA-IGA: Cutaneous Sarcoidosis Activity Investigator’s Global Assessment; KSQ: King’s Sarcoidosis Questionnaire
Page 14
For investor audiences only Brepocitinib 45 mg (n = 13) Brepocitinib 15 mg (n = 11) Placebo (n = 7) Mean Age (years) (± SD) 53.7 (8.14) 49.4 (11.57) 58.7 (6.18) Sex (Female) – no. (%) 11 (85%) 3 (27%) 4 (57%) Black race – no. (%) 11 (85%) 6 (55%) 6 (86%) Duration of Skin Disease (years) (± SD) 10.2 (9.49) 4.1 (2.06) 10.3 (7.18) Mean CSAMI-Activity Score (± SD) 34.9 (22.63) 32.4 (9.45) 32.9 (19.35) Mean CSA-IGA Activity Score (± SD) 2.8 (0.44) 3.3 (0.65) 3.0 (0.82) Plaque-predominant morphology* – no. (%) 11 (85%) 6 (55%) 3 (43%) Mean CSAMI-Damage Score (± SD) 6.1 (6.09) 3.2 (2.23) 5.7 (5.28) Background Therapy at Baseline – no. (%) Topical Corticosteroid 5 (39%) 4 (36%) 2 (29%) Systemic Therapy (OCS, IST, or AM) 8 (62%) 5 (45%) 3 (43%) Baseline Demographics & Disease Activity 45 mg arm was most treatment-refractory group with longstanding disease, high damage, and high rates of plaque- predominant morphology For investor audiences only *Large, thick lesions associated with chronic course and a higher likelihood of recurrence (Wanat, 2015) 14
Page 15
For investor audiences only Brepocitinib Achieved Rapid, Deep, Sustained Benefit on CSAMI-A CFB and IGA Clear/Almost Clear Brepocitinib 45 mg (n = 13) Brepocitinib 15 mg (n = 11) Placebo (n = 7) -30 -25 -20 -15 -10 -5 0 0 4 8 12 16 Mean Change from Baseline (± SE) Study Week -22.2 -22.3 -0.7 MCID * * * ** 0% 20% 40% 60% 80% 0 4 8 12 16 Percentage of Participants Study Week 55% 0% 69% * * Mean CSAMI-A Change from Baseline Achievement of IGA 0/1 and ≥ 2-Point Reduction * 45 mg vs. Placebo at Week 16: ∆ 69%; P=0.0047 45 mg vs. Placebo at Week 16: ∆ 21.6; P<0.0001 15P < 0.05; ** P < 0.0001 CSAMI-A: Cutaneous Sarcoidosis Activity and Morphology Instrument-Activity Score; MCID: minimal clinically important difference; IGA: investigator’s global assessment
Page 16
For investor audiences only Brepocitinib 45 mg (n = 13) Brepocitinib 15 mg (n = 11) Placebo (n = 7) 100% CSAMI-A Response Rate In Brepocitinib 45 mg Arm All 45 mg participants achieved ≥ 10-point CSAMI-A improvement (2x minimum clinically important difference) and 62% achieved functional remission 100% 73% 14% 45 mg vs. Placebo: ∆ 86%; P=0.0002 Achievement of CSAMI-A ≥ 10-point Reduction at Week 16 62% 46% 0% 45 mg vs. Placebo: ∆ 62%; P=0.0147 Achievement of CSAMI-A < 5 (Functional Remission) at Week 16 16All P values are nominal. CSAMI-A: Cutaneous Sarcoidosis Activity and Morphology Instrument-Activity Score; MCID: minimal clinically important difference
Page 17
For investor audiences only -24 -20 9 Skindex-16 Shows Substantial Improvements in Health-related Quality of Life Skindex-16 assesses health-related QoL 16 items in 3 domains: Symptoms Itching, Burning, Pain, Irritation Emotions Persistence, Worry, Frustration, Embarrassment, Depression Functioning Social interactions, Desire to be with others, Work and enjoyment of life Range 0 (best) to 100 (worst) Skindex-16 Overall Score Mean Reduction from Baseline to Week 16 45 mg vs. Placebo: ∆ 32; P=0.0027 Brepocitinib 45 mg (n = 13) Brepocitinib 15 mg (n = 11) Placebo (n = 7) MCID: -10 Skindex-16 Overall Score Reduction Improvement 17All P values are nominal. MCID: minimal clinically important difference
Page 18
For investor audiences only KSQ-Skin Domain Shows Substantial Improvements in Skin-Related Health Status 35 29 2 KSQ-Skin Domain Mean Change from Baseline to Week 16 Range: 0 (worst) to 100 (best) 45 mg vs. Placebo: ∆ 33; P=0.0054 Brepocitinib 45 mg (n = 13) Brepocitinib 15 mg (n = 11) Placebo (n = 7) KSQ-Skin Mean Change from Baseline Improvement KSQ assesses impact of CS on health status How much skin disease bothers the patient How much skin disease concerns the patient How much the patient is embarrassed by their skin 18All P values are nominal.
Page 19
For investor audiences only Brepocitinib 45 mg (n = 13) Brepocitinib 15 mg (n = 11) Placebo (n = 7) Patient Global Impression of Change (PGI-C) Show Dose-Dependent Improvements 100% 82% 29% 45 mg vs. Placebo: ∆ 71%; P=0.0014 Patient Global Impression of Change: Improved from Baseline At Week 16 PGI-C Asks Patients One Question: “Since you started taking study medication, how would you describe the overall change in your sarcoidosis skin symptoms?” Patients may check “no change,” one of 3 degrees of improvement (slightly, much, very much), or one of 3 degrees of worsening (slightly, much, very much) Of patients who did not report improvement o 18% of brepocitinib 15 mg patients reported worsening o 43% of placebo patients reported worsening, and 28% reported no change 19* Proposed definition. All P values are nominal. CSAMI-A: Cutaneous Sarcoidosis Activity and Morphology Instrument-Activity Score; MCID: minimal clinically important difference
Page 20
For investor audiences only Brepocitinib Was Well-Tolerated During Treatment Period, with No SAEs and All AEs Graded Mild or Moderate In Severity Brepocitinib 45 mg QD (N=13) Brepocitinib 15 mg QD (N=11) Placebo (N=7) Participants with: Adverse Events (AEs) 12 (92%) 6 (55%) 6 (86%) Death 0 0 0 AEs graded as severe 0 0 0 Serious Adverse Events (SAEs) 0 0 0 AEs leading to treatment discontinuation 1 (8%) 1 (9%) 1 (14%) AEs leading to study discontinuation 0 0 0 Adverse Events of Special Interest (AESI): Creatine Kinase (CK) Increased 1 (8%) 0 0 Anemia 1 (8%) 0 0 Viral reactivation 0 0 0 Malignancy 0 0 0 Major adverse cardiovascular event 0 0 0 Venous thromboembolism 0 0 0 Liver enzyme elevation 0 0 0 Other AESIs 0 0 0 20Note: CK elevation was asymptomatic, did not result in study drug discontinuation, and improved with continued treatment. Anemia re presented worsening of baseline anemia and improved following study drug discontinuation. Both AESIs were moderate in severity. Note: Percentages are based on the number of unique participants with an event. Treatment -emergent AEs during treatment period are r eported.
Page 21
For investor audiences only Concluding Thoughts • Compelling evidence of clinical benefit in a disease with no approved therapies • Brepocitinib demonstrated rapid onset of action and sustained benefit on CSAMI-A at every timepoint measured • More than two thirds of brepocitinib 45 mg patients achieved IGA clear/almost clear with two-point improvement, compared to 0 placebo patients • Patient reported outcomes support findings from clinician-administered endpoints and highlight evidence of dose-dependent benefit • Safety data supports potentially favorable benefit:risk profile, consistent with past brepocitinib studies and safety profile of approved JAK1 and TYK2 targeted agents • Priovant intends to initiate a Phase 3 program by the end of calendar year 2026, following engagement with FDA • Cutaneous sarcoidosis represents third large orphan indication with high patient burden and few/no treatment options in which brepocitinib could potentially be approved within the next few years 21
Page 22
For investor audiences only Brepocitinib Poised to Address >150K Patients With Continuous Catalyst Flow Over the Next 12-24 Months Dermatomyositis NDA Filed Cutaneous Sarcoidosis Positive Ph2 Topline Data Non-Infectious Uveitis Ph3 Topline Data (2H 2026) Dermatomyositis Potential NDA Approval ~70K Patients (DM) ~110K Patients (DM + NIU) ~150K Patients (DM + NIU + CS) Non-Infectious Uveitis Potential sNDA Approval Cutaneous Sarcoidosis Ph3 Ongoing Cutaneous Sarcoidosis Potential sNDA Approval Today Late 2026 / Early 2027 Late 2027 / Early 2028 2028+ Continued Momentum Across Brepocitinib Franchise with Positive Ph2 Data in CS: Ph3 Study Initiation Expected in 2026 Additional Indications Development ongoing Illustrates ~10K patients. Note: All drugs are investigational and subject to regulatory approvals. All catalyst timings are approximate, based on current expectations and, where applicable, contingent on FDA feedback, and may be subject to change. All references are to calendar years. 22
Page 23
Additional Program Highlights
Page 24
For investor audiences only 24 IMVT-1402 Highlights Potential Best-in-Class Efficacy IMVT-1402 achieves deep, rapid, dose- dependent IgG reductions; consistent evidence across external and internal clinical trials validates that deeper IgG reductions lead to greater clinical benefit EXPLORE Phase 3 Study in D2T RA Now Fully Enrolled (N = 170 versus anticipated 120) Favorable Safety Profile No significant expected safety issues based on data to-date Pipeline-in-a-Product Potential IMVT-1402 is on track to be potential first- and/or best-in-class treatment across 6 indications with potential to address more than 600K patients 1 in the US Convenient Administration Simple subcutaneous autoinjector with 5-10 second self- administration; currently being tested in all IMVT-1402 trials Note: All drugs are investigational and subject to regulatory approvals. All catalyst timings are approximate, based on current expectations and, where applicable, contingent on FDA feedback, and may be subject to change. All references are to calendar years. 1. Addressable populations are listed in IMVT Pipeline in IMVT Corporate Overview deck
Page 25
For investor audiences only 25 Mosliciguat Highlights Note: All drugs are investigational and subject to regulatory approvals. All catalyst timings are approximate, based on current expectations and, where applicable, contingent on FDA feedback, and may be subject to change. All references are to calendar years. 1. Evidenced by data demonstrated in ATMOS and Phase 1 studies conducted in healthy volunteers 2. Becker-Peslster et al., Respir Res (2022) PH-ILD MOSLICIGUAT Lung is the primary site of the disease Target delivery to the lungs with deep lung deposition1 High dosing burden with multiple daily inhalations Convenient once-daily dosing Current therapies are poorly tolerated and can increase cough Well-tolerated, with limited cough and systemic side effects1 Interplay of vascular remodeling and parenchymal scarring Promotes vasodilation1,2 and may exert antifibrotic and anti-inflammatory effects2 1x day cGMP PHocus Phase 2 Study in PH-ILD Now Fully Enrolled
Page 26
For investor audiences only Pivotal Period for LNP Litigation Moderna Cases Pfizer Case Ongoing progress in discovery phase Favorable Markman ruling issued September 2025 Note: All references are to calendar years and are approximate and subject to change. The timing of the litigation-related events noted above is subject to change, including at the discretion of the court. See Slide 2 for further information on these forward-looking statements 26 Revocation of European Patent EP 2279254 is Not Expected to Impact Litigation in Other Jurisdictions Pre-trial process to narrow scope of claims and defenses Favorable summary judgment decision in U.S. Moderna case affirms Genevant's view of section 1498: significant majority of liability belongs in current case against Moderna US jury trial scheduled for March 9, 2026 First major international hearings expected in 1H 2026
Page 27
Financial Update
Page 28
For investor audiences only Key Financial Items • R&D expense of $165M; adjusted R&D expense of $147M (non-GAAP) • G&A expense of $175M; adjusted G&A expense of $71M (non-GAAP) • Loss from continuing operations, net of tax of $314M; adjusted loss from continuing operations, net of tax of $167M (non-GAAP) Select Income Statement Metrics and Non-GAAP Metrics for the Three Months Ended December 31, 2025 • Cash, cash equivalents, restricted cash and marketable securities of $4.5BN • No debt on balance sheet • 715,701,137 common shares issued and outstanding as of February 2, 2026 Select Balance Sheet Metrics as of December 31, 2025 Note: For a reconciliation of each non-GAAP financial metric to the comparable GAAP financial metric, please see slide 29 28
Page 29
For investor audiences only Non-GAAP Disclosures (1) Represents non-cash share-based compensation expense. (2) Represents non-cash depreciation and amortization expense. (3) Represents a loss on impairment of the operating lease right-of-use asset and leasehold improvements for the former U.S. corporate headquarters of Roivant Sciences, Inc., following relocation to a new office space and execution of an agreement to sublease the former office space during the three months ended December 31, 2025. (4) Represents the unrealized (gain) loss on equity investments in unconsolidated entities that are accounted for at fair value with changes in value reported in earnings. (5) Represents the change in fair value of liability instruments, which is non-cash and primarily includes the loss (gain) relating to the measurement and recognition of fair value on a recurring basis of certain liabilities. (6) Represents the estimated tax effect of the adjustments. Notes to non-GAAP financial measures: Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited, in thousands) 29 Three Months Ended December 31, Note 2025 2024 Loss from continuing operations, net of tax $ (313,701) $ (208,945) Adjustments: Research and development: Share-based compensation (1) 18,123 9,685 Depreciation and amortization (2) 548 728 General and administrative: Share-based compensation (1) 86,874 69,386 Depreciation and amortization (2) 142 1,083 Impairment loss from relocation of Roivant Sciences, Inc.'s headquarters (3) 17,098 — Other: Change in fair value of investments (4) (21,592) 21,314 Change in fair value of liability instruments (5) 24,416 (2,147) Estimated income tax impact from adjustments (6) 21,058 (34,786) Adjusted loss from continuing operations, net of tax (Non-GAAP) $ (167,034) $ (143,682) Three Months Ended December 31, Note 2025 2024 Research and development expenses $ 165,380 $ 141,595 Adjustments: Share-based compensation (1) 18,123 9,685 Depreciation and amortization (2) 548 728 Adjusted research and development expenses (Non-GAAP) $ 146,709 $ 131,182 Three Months Ended December 31, Note 2025 2024 General and administrative expenses $ 175,072 $ 141,545 Adjustments: Share-based compensation (1) 86,874 69,386 Depreciation and amortization (2) 142 1,083 Impairment loss from relocation of Roivant Sciences, Inc.'s headquarters (3) 17,098 — Adjusted general and administrative expenses (Non-GAAP) $ 70,958 $ 71,076
Page 30
For investor audiences only Program Vant Catalyst Expected Timing Roivant pipeline growth New mid/late-stage in-licensing announcements Ongoing LNP platform Summary judgment phase in US Moderna case Ongoing LNP platform Jury trial in US Moderna case March 2026 Brepocitinib Expected NDA filing for brepocitinib in dermatomyositis Brepocitinib Topline data from Phase 2 trial in cutaneous sarcoidosis Batoclimab Topline data from both Phase 3 trials in thyroid eye disease 1H 2026 LNP platform First major hearings in ex-US Moderna cases 1H 2026 Mosliciguat Topline data from Phase 2 trial in pulmonary hypertension associated with interstitial lung disease 2H 2026 Brepocitinib Topline data from Phase 3 trials in non-infectious uveitis 2H 2026 IMVT-1402 Topline data from Phase 2 trial in cutaneous lupus erythematosus 2H 2026 IMVT-1402 Topline data from potentially registrational trial in ACPA+ difficult-to-treat rheumatoid arthritis 2H 2026 IMVT-1402 Topline data from potentially registrational trials in Graves’ disease 2027 IMVT-1402 Topline data from potentially registrational trial in myasthenia gravis 2027 IMVT-1402 Topline data from potentially registrational trial in Sjögren’s disease 2028 IMVT-1402 Topline data from potentially registrational trial in chronic inflammatory demyelinating polyneuropathy 2028 Rich Catalyst Calendar 30 Note: All drugs are investigational and subject to regulatory approvals. All catalyst timings are based on current expectations and, where applicable, contingent on FDA feedback, and may be subject to change. The timing of the litigation-related events noted above is subject to change, including at the discretion of the court. All references are to calendar years
Page 31
For investor audiences only 31 Over the Next 36 Months (by End of CY 2028), Roivant Will Execute on… Note: All drugs are investigational and subject to regulatory approvals. All catalyst timings are approximate, based on current expectations and, where applicable, contingent on FDA feedback, and may be subject to change. All references are to calendar years. Green outline and check indicate successful execution NDA: new drug application; BLA: biologics license application; DM: dermatomyositis; NIU: non-infectious uveitis; GD: Graves’ disease; MG: myasthenia gravis; CIDP: chronic inflammatory demyelinating polyneuropathy; SjD: Sjögren's disease; D2T RA: difficult-to-treat rheumatoid arthritis; PH-ILD: pulmonary hypertension with interstitial lung disease; CLE: cutaneous lupus erythematosus; CS: cutaneous sarcoidosis *May be supplementary filings, depending on drug/indication 4+ NDA/BLA Filings* 9+ Pivotal Study Readouts 3+ POC Study Readouts Across 3+ Indications PH-ILD CLE Across 7+ Indications brepocitinib IMVT-1402 GD MG NIUDM 3+ Commercial Launches brepocitinib IMVT-1402 mosliciguat brepocitinib IMVT-1402 GD NIUDM CS NIU CIDPMGCS SjD D2T RAGD
Page 32
Thank you.